Magenta Therapeutics   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03406962
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Magenta Therapeutics | Magenta Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

mgta-145 (3 trials)

mgta-456 (1 trial)

plerixafor (mozobil) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 2)

Metabolic Diseases (Phase 2)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3